Q1 Adjusted Corporate Expenses increase driven by higher technology infrastructure investments

ir_statement / Sep 17, 2026 / receipt

Raising Fiscal 2027 Adjusted EPS Outlook

ir_statement / Sep 17, 2026 / receipt

Corporate Expenses $580 to $640 million

ir_statement / Sep 17, 2026 / receipt

Earnings per Diluted Share $44.20 to $45.00 Previously $43.80 to $44.60

ir_statement / Sep 17, 2026 / receipt

Operating Profit 9% to 13% growth Previously 8% to 12% growth

ir_statement / Sep 17, 2026 / receipt

Share Repurchases Approximately $5.0 billion

ir_statement / Sep 17, 2026 / receipt

Previously 5.5% to 9.5% growth

ir_statement / Sep 17, 2026 / receipt

Restructuring, impairment, and related charges, net for the three months ended June 30, 2026 includes pre-tax charges of $136 million ($100 million after-tax), primarily within Prescription Technology

ir_statement / Sep 17, 2026 / receipt

Transaction-related expenses and adjustments for the three months ended June 30, 2026 includes a charge of $81 million (pre-tax and after-tax), within Oncology & Multispecialty, related to the remeasu

ir_statement / Sep 17, 2026 / receipt

RAISED FISCAL 2027 GUIDANCE FOR ADJUSTED EARNINGS PER DILUTED SHARE TO $44.20 to $45.00

ir_statement / Sep 17, 2026 / receipt

Sr. Software Engineer | {"ats": "workday", "city": null, "state": null, "job_id": "/job/USA-OH-Columbus/Sr-Software-Engineer_JR0153440-2", "remote": false, "category": "other", "function": "engineerin

company_statement / Sep 11, 2026 / receipt

Sr. Specialist, Software Development & Engineering | {"ats": "workday", "city": null, "state": null, "job_id": "/job/USA-OH-Columbus/Sr-Specialist--Software-Development---Engineering_JR0153022", "remo

company_statement / Sep 1, 2026 / receipt